- Latest Stories
- Commentary and Analysis
9:40AM ET 11/10/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
6:01AM ET 8/25/2022 MT NewswiresProtagonist Therapeutics (PTGX) has an average rating of outperform and price targets ranging from $21 to $50, according to analysts polled by Capital IQ....
6:52AM ET 5/18/2022 MT NewswiresProtagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...
10:00AM ET 5/05/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
2:54PM ET 4/26/2022 MT NewswiresProtagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...
1:50PM ET 4/26/2022 MT NewswiresProtagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...
7:55AM ET 4/26/2022 MT NewswiresProtagonist Therapeutics (PTGX) shares slumped 33% after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis. InMed...
3:56PM ET 4/14/2022 MT NewswiresHealth care stocks were narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.1% and the SPDR Health Care Select Sector ETF (XLV) down...
1:58PM ET 4/14/2022 MT NewswiresProtagonist Therapeutics (PTGX) said it received a letter from the Food and Drug Administration indicating the regulator's intention to rescind...
1:36PM ET 4/14/2022 MT Newswires(Updates with the stock move in the second paragraph and headline.) Protagonist Therapeutics (PTGX) said late on Wednesday it received a letter from the...